Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Routine Continuous Monitoring After Angioplasty Might Not Be Necessary

According to a recent study published in Circ. Cardiovasc Interv, after a scheduled angioplasty, the rate of arrhythmia requiring some kind of treatment is very low, low enough to deem unnecessary the routine monitoring of all patients.

Monitoreo Post Angioplastia

The standard policy at many institutions is continuous cardiac monitoring for several hours after undergoing coronary angioplasty, with its subsequent discomfort and monetary costs.

More thorough monitoring of patients who are at risk for arrhythmia seems a reasonable strategy. The at-risk group might include patients with acute coronary syndrome, left main or multivessel disease, hemodynamic instability, and patients with “less than perfect” angioplasty outcomes.

This study included 1278 consecutive procedures between 2015 and 2017. According to hospital policy, all angioplasties were followed by cardiac monitoring for a mean 24 hours. For this analysis, patients were divided in groups depending on whether they experienced arrhythmia requiring treatment or not.


Read also: Reliability of FFR in Patients with Diabetes: Are Other Parameters Necessary?


Overall, there were 1672 arrhythmias during the post-procedure period. Among them, only 37 (2.2%) were actual medically actionable alarms. There were 20 cases of bradyarrhythmia and 17 cases of tachyarrhythmia, with an average of 5.5 hours post-procedure.

Patient factors associated with arrhythmia requiring treatment were acute coronary syndrome, older age, left main disease, and multivessel disease.

Among patients with arrhythmia, 30-day mortality was 6.5% vs. 0.3% for those with no arrhythmia (p < 0.0001).


Read also: New European Guidelines for Dyslipidemia Management: What is New?


Additionally, having an arrhythmia alarm activated was associated with permanent pacemaker and implantable cardioverter-defibrillator, patient transfer to a coronary unit, and use of class I and III antiarrhythmic drugs.

The results of this work are more hypothesis-generating than definitive. Many physicians might voice some concerns (even of legal nature) about not monitoring patients after angioplasty.

Original Title: Routine continuous electrocardiographic monitoring following percutaneous coronary interventions.

Reference: Al-Hijji MA et al. Circ Cardiovasc Interv. 2020;13:e008290.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...